Clinical trial Recruiting at 1 site Interventional Ages 50 to 65

Progressive Blood Flow Restriction Exercises After Total Knee Replacement

Official title: Effects of Progressive Restricted Blood Flow Exercise on Pain, Range of Motion, Swelling, Proprioception and Kinesiophobia on Patients With Total Knee Arthoplasty

Run by Lahore University of Biological and Applied Sciences · NCT07601906 · Data updated 2026-11-12

In people aged 50–65 who had a knee replacement, this study tests whether adding progressive blood flow restriction exercises to standard physical therapy helps recovery.

Quick facts

Study typeInterventional
Ages50 Years to 65 Years
SexAll
Enrollment48 (estimated)
SponsorLahore University of Biological and Applied Sciences
Academic / other
Locations1 site (Lahore, Punjab Province)
StatusRecruiting
StartedMay 25, 2026
Main results expectedOctober 31, 2026
Study endsNovember 20, 2026
Registry record updatedJune 9, 2026
Trial IDNCT07601906 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults 50–65 years old who had a primary unilateral TKA for osteoarthritis, experience mild to moderate pain after surgery, and can actively move the knee with at least 30° flexion.

Probably not a fit

Patients with recent deep vein thrombosis, severe cardiovascular conditions, vascular disease, active infection, or significant neurological impairment may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, single-blind trial compares progressive blood flow restriction (BFR) exercise plus conventional physical therapy to conventional physical therapy alone after unilateral total knee arthroplasty. The goal is to see if BFR can improve pain, range of motion, swelling, and function without excessive joint stress. Participants will be adults with mild to moderate postoperative pain and specific knee motion criteria, recruited from a Lahore, Pakistan site. Outcomes will include pain levels, knee flexion, swelling, and proprioception, among other functional measures. The trial uses a two-arm parallel design to evaluate the added value of BFR in the early rehabilitation period.

Why it matters

Potential benefit: If successful, patients may regain knee function faster with less pain and swelling using lower-load exercises.

How similar studies have gone: Previous research supports BFR for improving muscle strength; effects on other outcomes after TKA are less established, making this study relatively novel in broader outcome assessment.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients of age 50-65 years.
2. Primary unilateral TKA due to osteoarthritis.
3. Individuals with mild to moderate postoperative pain (NPRS score 4-7).
4. Minimum active knee flexion of 30° \& an extension lag of no more than 15°.
5. Patients should be medically stable, cognitively able to follow instructions in Urdu or english, and willing to provide written informed consent

Exclusion Criteria:

1. History of deep vein thrombosis within the last six months.
2. Peripheral vascular disease and active infection.
3. Severe cardiovascular conditions
4. Neurological disorders affecting lower limb function

Where it's running

  • Saleem Memorial Trust Hospital
    Lahore, Punjab Province, Pakistan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.